AAAAAA

   
Results: 1-17 |
Results: 17
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer
Authors: Reles, A Wen, WH Schmider, A Gee, C Runnebaum, IB Kilian, U Jones, LA El-Naggar, A Minguillon, C Schonborn, I Reich, O Kreienberg, R Lichtenegger, W Press, MF
Citation: A. Reles et al., Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer, CLIN CANC R, 7(10), 2001, pp. 2984-2997
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta(3) subunit expression and increased by reconstitution of integrin alpha(V)beta(3)
Authors: Bruning, A Kohler, T Quist, S Wang-Gohrke, S Moebus, VJ Kreienberg, R Runnebaum, IB
Citation: A. Bruning et al., Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta(3) subunit expression and increased by reconstitution of integrin alpha(V)beta(3), HUM GENE TH, 12(4), 2001, pp. 391-399
Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines
Authors: Stickeler, E Therasakvichya, S Moebus, VJ Kieback, DG Runnebaum, IB Kreienberg, R
Citation: E. Stickeler et al., Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines, ONCOL REP, 8(6), 2001, pp. 1381-1386
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
Authors: Runnebaum, IB Wang-Gohrke, S Vesprini, D Kreienberg, R Lynch, H Moslehi, R Ghadirian, P Weber, B Godwin, AK Risch, H Garber, J Lerman, C Olopade, OI Foulkes, WD Karlan, B Warner, E Rosen, B Rebbeck, T Tonin, P Dube, MP Kieback, DG Narod, SA
Citation: Ib. Runnebaum et al., Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives, PHARMACOGEN, 11(7), 2001, pp. 635-638
Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells
Authors: Saretzki, G Ludwig, A von Zglinicki, T Runnebaum, IB
Citation: G. Saretzki et al., Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells, CANC GENE T, 8(10), 2001, pp. 827-834
Epidemiological and molecular aspects of ovarian cancer risk
Authors: Runnebaum, IB Stickeler, E
Citation: Ib. Runnebaum et E. Stickeler, Epidemiological and molecular aspects of ovarian cancer risk, J CANC RES, 127(2), 2001, pp. 73-79
Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients
Authors: Stickeler, E Vogl, FD Denkinger, T Mobus, VJ Kreienberg, R Runnebaum, IB
Citation: E. Stickeler et al., Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients, INT J MOL M, 6(5), 2000, pp. 595-601
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro
Authors: Wu, Q Kreienberg, R Runnebaum, IB
Citation: Q. Wu et al., Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro, J CANC RES, 126(3), 2000, pp. 139-144
Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50
Authors: Wang-Gohrke, S Chang-Claude, J Becher, H Kieback, DG Runnebaum, IB
Citation: S. Wang-gohrke et al., Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50, CANCER RES, 60(9), 2000, pp. 2348-2350
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass
Authors: Vogl, FD Frey, M Kreienberg, R Runnebaum, IB
Citation: Fd. Vogl et al., Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass, BR J CANC, 83(10), 2000, pp. 1338-1343
Multiplex PCR (MPCR) screening can detect small intragenic p53 deletion and insertion mutations
Authors: Runnebaum, IB Wang-Gohrke, S
Citation: Ib. Runnebaum et S. Wang-gohrke, Multiplex PCR (MPCR) screening can detect small intragenic p53 deletion and insertion mutations, METH MOL M, 39, 2000, pp. 329-335
Intrauterine resuscitation by rapid urinary bladder instillation in a caseof occult prolapse of an excessively long umbilical cord
Authors: Runnebaum, IB Katz, M
Citation: Ib. Runnebaum et M. Katz, Intrauterine resuscitation by rapid urinary bladder instillation in a caseof occult prolapse of an excessively long umbilical cord, EUR J OB GY, 84(1), 1999, pp. 101-102
p53 mutations and expression in ovarian cancers: Correlation with overall survival
Authors: Wen, WH Reles, A Runnebaum, IB Sullivan-Halley, J Bernstein, L Jones, LA Felix, JC Kreienberg, R El-Naggar, A Press, MF
Citation: Wh. Wen et al., p53 mutations and expression in ovarian cancers: Correlation with overall survival, INT J GYN P, 18(1), 1999, pp. 29-41
p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells
Authors: Vogl, FD Stickeler, E Weyermann, M Kohler, T Grill, HJ Negri, G Kreienberg, R Runnebaum, IB
Citation: Fd. Vogl et al., p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells, ONCOL-BASEL, 57(4), 1999, pp. 324-329
Malignant hemangiopericytoma of the uterus - A case report
Authors: Regele, S Vogl, FD Runnebaum, IB Kreienberg, R Bohm, W
Citation: S. Regele et al., Malignant hemangiopericytoma of the uterus - A case report, GEBURTSH FR, 59(6), 1999, pp. 293-295
Sevum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast
Authors: Regele, S Kohlberger, P Vogl, FD Bohm, W Kreienberg, R Runnebaum, IB
Citation: S. Regele et al., Sevum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast, BR J CANC, 81(4), 1999, pp. 702-704
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
Authors: Wang-Gohrke, S Weikel, W Risch, H Vesprini, D Abrahamson, J Lerman, C Godwin, A Moslehi, R Olipade, O Brunet, JS Stickeler, E Kieback, DG Kreienberg, R Weber, B Narod, SA Runnebaum, IB
Citation: S. Wang-gohrke et al., Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations, BR J CANC, 81(1), 1999, pp. 179-183
Risultati: 1-17 |